Challenging AQP4 druggability for NMO-IgG antibody binding using molecular dynamics and molecular interaction fields

Area of Science:

• Neuroimmunology
• Structural Biology
• Computational Chemistry

Background:

• Neuromyelitis optica (NMO) is an autoimmune disease targeting the central nervous system.
• NMO is characterized by autoantibodies (NMO-IgG) against Aquaporin-4 (AQP4) water channels.
• Understanding NMO-IgG binding mechanisms is crucial for developing targeted NMO therapies.

Purpose of the Study:

• To investigate the molecular mechanisms by which point mutations in AQP4 affect NMO-IgG binding.
• To explore the potential for AQP4 as a drug target for NMO treatment.

Main Methods:

• Extensive Molecular Dynamics (MD) simulations of single-point AQP4 mutants.
• Molecular Interaction Fields (MIF) analysis to identify potential drug-binding sites.
• Molecular docking studies to assess drug-like compound interactions.

Main Results:

• A point mutation at AQP4 position 69 (D69) induces a domino effect, reorienting residue T62 and weakening a key H-bond interaction (L53-T56).
• These structural changes prevent NMO-IgG binding to AQP4.
• AQP4 water channel function and aggregation into OAPs remain unaffected by the mutation.
• MIF analysis identified a potential binding site involving residues critical for epitope reorganization.

Conclusions:

• The D69 mutation provides a mechanistic explanation for the failure of NMO-IgG binding.
• This study highlights AQP4's druggability and offers a computational basis for designing novel NMO therapeutics.
• The findings pave the way for developing small molecule drugs targeting NMO.